XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer
| Autor: | Hugo Veyssière, Sejdi Lusho, Judith Passildas, Mathias Cavaillé, Angeline Ginzac, Nina Radosevic-Robin, Ioana Molnar, Xavier Durando, Yannick Bidet, Maureen Bernadach |
|---|---|
| Přispěvatelé: | Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, COLO, Mouniati |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
0301 basic medicine medicine.medical_specialty Luminal B breast cancer viruses [SDV]Life Sciences [q-bio] Breast Neoplasms [SDV.CAN]Life Sciences [q-bio]/Cancer General Biochemistry Genetics and Molecular Biology Metastatic tumours Study Protocol 03 medical and health sciences Breast cancer 0302 clinical medicine [SDV.CAN] Life Sciences [q-bio]/Cancer Neoadjuvant treatment Internal medicine Humans Medicine Triple negative breast cancer Prospective Studies General Pharmacology Toxicology and Pharmaceutics Prospective cohort study Triple negative Triple-negative breast cancer ComputingMilieux_MISCELLANEOUS Luminal B Breast Cancer General Immunology and Microbiology Patient-Derived Xenografts business.industry Ethics committee virus diseases Articles General Medicine biochemical phenomena metabolism and nutrition medicine.disease Neoadjuvant Therapy digestive system diseases 3. Good health [SDV] Life Sciences [q-bio] 030104 developmental biology 030220 oncology & carcinogenesis Interventional research Heterografts Female business 030217 neurology & neurosurgery |
| Zdroj: | F1000Research F1000Research, Faculty of 1000, 2020, 9, pp.1219. ⟨10.12688/f1000research.26873.1⟩ |
| ISSN: | 2046-1402 |
| DOI: | 10.12688/f1000research.26873.1⟩ |
| Popis: | Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX from primitive mammary tumours or after neoadjuvant treatment are still rare. This study aims to assess the feasibility to establish xenografts from tumour samples of patients with triple negative or luminal B breast cancer in neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a single-centre and prospective study. This feasibility pilot trial aims to produce xenografts from tumour samples of patients with triple negative or luminal B breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be enrolled and followed for 28 months. Additional blood samples will be taken as part of the study. Surgical specimens from post-NAC surgery, primary surgery or surgical excision of the metastases will be collected to establish PDX. Histomolecular characteristics of the established PDX will be investigated and compared with the initial histomolecular profile of the collected tumours to ensure that they are well-established. Ethics and dissemination: XENOBREAST belongs to category 2 interventional research on the human person. This study has been approved by the Sud Méditerranée IV – Montpellier ethics committee. It is conducted notably in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study data and findings will be published in peer-reviewed medical journals. We also plan to present the study and all data at national congresses and conferences. Registration: ClinicalTrials.gov ID NCT04133077; registered on October 21, 2019. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|